The analyst rating for CSPC Pharma (01093.HK) is maintained at "Underperform" by BofAS due to sales pressure, despite the positive developments in their collaboration with AstraZeneca and the potential for milestone revenue recognition from their R&D pipeline. CICC, on the other hand, raised its target price to $12 and kept its rating at "Outperform," reflecting confidence in the company's earnings forecasts and innovative assets.